Cosmetic cross-reference

Pyridoxal

CAS 66-72-8

Pyridoxal (CAS 66-72-8) is a Phase 3 pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
4
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Pyridoxal
CAS Number
66-72-8
UNII
3THM379K8A
InChIKey
RADKZDMFGJYCBB-UHFFFAOYSA-N
ChEMBL ID
CHEMBL102970
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 3
Late-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL102970 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 34886.75833333333 nM 12 -
- AC50 7996 nM 2 -
- IC50 19976.309999999998 nM 1 -
- Ki 30000 nM 1 -
Aldehyde oxidase
Enzyme
Ki 4.52 - Homo sapiens
SOURCE DrugCentral 5 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Hepatic function abnormal 39 104.318 10019670
Interstitial lung disease 41 93.301 10022611
Palmar-plantar erythrodysaesthesia syndrome 21 56.848 10033553
Platelet count decreased 30 42.739 10035528
Osteonecrosis of jaw 18 42.387 10064658

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Pyridoxal used for in pharmaceutical contexts?

Pyridoxal (CAS 66-72-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Pyridoxal?

Pyridoxal has 0 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hepatic function abnormal, Interstitial lung disease, Palmar-plantar erythrodysaesthesia syndrome, Platelet count decreased, Osteonecrosis of jaw. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Pyridoxal also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Pyridoxal with EU status "permitted".

What clinical phase is Pyridoxal in?

Pyridoxal is rendered with ChEMBL max phase 3.

What bioactivity targets are documented for Pyridoxal?

Pyridoxal has 4 bioactivity rows in this page query. Rendered target entries include Aldehyde oxidase.